DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Opana (Oxymorphone Hydrochloride) - Summary

 
 



OPANA SUMMARY

OPANA (oxymorphone hydrochloride) is a semi-synthetic opioid analgesic supplied in 5 mg and 10 mg tablet strengths for oral administration. The tablet strengths describe the amount of oxymorphone hydrochloride per tablet.

OPANA is indicated for the relief of moderate to severe acute pain where the use of an opioid is appropriate.


See all Opana indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Opana (Oxymorphone)

'Smoke alarm' one of 36 genes newly found to play role in pain sensation
Source: Genetics News From Medical News Today [2016.06.24]
Genes identified as affecting nerve sensitivity in fruit flies could represent future drug targets in human pain management.

Opioid Update: Painkiller Misuse in U.S. Doubled in Decade
Source: MedicineNet Drug Abuse Specialty [2016.06.24]
Title: Opioid Update: Painkiller Misuse in U.S. Doubled in Decade
Category: Health News
Created: 6/24/2016 12:00:00 AM
Last Editorial Review: 6/24/2016 12:00:00 AM

SPECT/CT Improves Back Pain Management
Source: Medscape Radiology Headlines [2016.06.22]
Treating chronic back pain can be complex, but SPECT/CT can help clinicians clearly identify the site of pain to improve the precision of nerve block injections, a new study suggests.
Medscape Medical News

Long-term opioids may not be best pain management option for all sickle cell patients
Source: Genetics News From Medical News Today [2016.06.22]
Small study shows some on opioids reported more pain, fatigue.In a small study looking at pain assessments in adults with sickle cell disease, researchers at Johns Hopkins says overall, those...

OTC Antacids Linked to Bleeding Risk: The Pain Medicine News Report
Source: MedPage Today Rheumatology [2016.06.22]
(MedPage Today) -- Also, new Hopkins program to diminish opioid overdose

more news >>

Published Studies Related to Opana (Oxymorphone)

Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
OBJECTIVE: To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSIONS: At equianalgesic doses, single oral intact OM-ER produced lower positive, negative, and balance subjective effects than OC-CR, indicating that analgesic potency may not necessarily be reflected in subjective/objective effects.

Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
BACKGROUND: Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects. OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSION: Single oral intact low and high doses of OM-ER produced less cognitive and psychomotor impairment plus less sedation than equianalgesic OC-CR in this exploratory study. ClinicalTrials.gov registration NCT00955110.

Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. [2010.05]
OBJECTIVE: To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain... CONCLUSIONS: In these patients with pain related to cancer, oxymorphone ER was generally well tolerated and provided stable long-term pain control.

The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
OBJECTIVE: In controlled trials of analgesics, the primary outcome variable is most often a measure of global pain intensity. However, because pain is associated with a variety of pain sensations, the effects of analgesic treatments on different sensations could go undetected if specific pain qualities are not assessed...

Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
OBJECTIVE: This study assessed the potential effects of age, sex, and prior opioid use on the response to oxymorphone extended release (ER) in patients with moderate to severe chronic low back pain... CONCLUSION: In the enriched population of patients who successfully titrated to oxymorphone ER, oxymorphone ER was effective and generally well tolerated, independent of patients' age, sex, or previous opioid use.

more studies >>

Clinical Trials Related to Opana (Oxymorphone)

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions [Completed]
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone hydrochloride extended-release tablets (Sandoz) with Opana extended release oxymorphone hydrochloride tablets.

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects [Terminated]
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s) every 12 hours. Dosing adjustments will be based on the review of the subject's pain scores. Oxymorphone IR 5 mg will be provided to be used as supplemental "breakthrough" pain medication (as needed). Titration Period will end when the fixed dose of study medication is tolerated and the subject achieves adequate analgesia. Subjects will then proceed to the open-label 3-month maintenance period on the fixed dose of study medication established during the Titration Period.

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin) [Completed]

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions [Completed]
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone hydrochloride extended release tablets (Sandoz) with Opana extended release oxymorphone hydrochloride tablets.

Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions [Completed]
The objective of this study was to prove the bioequivalence of Oxymorphone Hydrochloride 10 mg Tablets under fasting conditions

more trials >>

Reports of Suspected Opana (Oxymorphone) Side Effects

Drug Abuse (22)Drug Ineffective (20)Insomnia (19)Weight Decreased (15)Drug Dependence (15)Respiratory Depression (12)Agitation (11)Tinnitus (11)Intentional Drug Misuse (11)Pain (10)more >>


Page last updated: 2016-06-24

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015